Xenetic Biosciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.2M
- Price
- $2.21
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.25%
- Volume
- 15.6K
About
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Quick stats
Shares outstanding2.3M
Computed float2.1M
Float / shares90.0%
Cash runway (months)31.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001534525
Websitehttps://www.xeneticbio.com
AI Summary
AI-generated1/10
criticalmixedm and a
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Xenetic Biosciences (NASDAQ: XBIO) has signed a definitive all-stock share exchange agreement to acquire Santersus AG, with the combined company to be renamed Santersus Bio, Inc. and trade on Nasdaq under a new ticker, SNTS.
On a pro forma fully diluted basis, current Xenetic equity holders will own approximately 15.0% of the combined company while Santersus holders receive about 85.0%, subject to adjustment based on Xenetic's net cash at closing. The deal is expected to close in Q4 2026, pending Xenetic stockholder approval, Nasdaq listing of the new shares, and effectiveness of a resale S-1.
The combined pipeline comprises four first-in-class NET-targeting programs, including pivotal-stage NucleoCapture studies in sepsis and systemic lupus erythematosus — each with FDA Breakthrough Device Designation — plus a Phase 1b study pairing Xenetic's DNase with anti-CD19 CAR-T cells in large B-cell lymphoma.
Santersus CEO James Ladtkow will lead the combined company with a board of eight split six Santersus nominees to two Xenetic nominees, and key equity holders, directors and officers have signed 180-day post-closing lock-ups.
Red flags
- Existing XBIO stockholders diluted to ~15.0% of the combined company (Santersus holders receive ~85.0%)
- Closing contingent on Xenetic stockholder approval, Nasdaq listing of new shares, and S-1 effectiveness — deal failure risk
- Forward-looking statements cite potential need for a reverse stock split to satisfy Nasdaq listing requirements post-close
- Ownership split subject to adjustment based on Xenetic's net cash at closing, creating exchange-ratio uncertainty
- No deal value disclosed; 180-day lock-ups will restrict post-closing liquidity for insiders